Background: We hypothesized that, among molecular subclasses of breast cancer, p53 status may have a differential predictive value for the efficacy of anthracyclines/alkylating agents-based regimen. We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification.
background
Combination regimens which include anthracyclines (epirubicin, doxorubicin) and alkylating agents (cyclophosphamide) administered in an adjuvant setting have been shown to improve overall survival in patients with early breast cancer [1] . While effective, this treatment presents some long-term haematological and cardiac side-effects [1] . Predictive factors of response would help to assess the expected individual benefit of this treatment. p53 has been one of the mostly investigated predictive biomarker for the efficacy of anthracyclines-containing regimen in the last two decades [2] [3] [4] [5] . Nevertheless, studies did not provide consistent results to conclude about the predictive value of p53 for the efficacy of chemotherapy in breast cancer. There is no unique explanation to date to account for such high inconsistencies across studies.
p53, the product of the TP53 tumour suppressor gene, is a nuclear protein and, when activated, is responsible for the cellular response to DNA damages: cell cycle arrest, DNA repair and/or apoptosis triggering [6] . DNA-damaging drugs function in a p53-dependent manner and p53 disruption makes numerous human cancer cells more sensitive to apoptosis induced by adriamycin in vitro [7, 8] . Inactivation of p53 function is more likely to occur in tumours with BRCA1 mutations that exhibit a basal-like phenotype [9] [10] [11] . Interestingly, anthracycline-induced apoptosis has been reported to be p53 mediated in luminal, but not in basal-like tumours [12] . When associated with BRCA1 mutations, p53 mutations were more likely to predict high sensitivity to anthracyclines in vitro [13] . In addition, it must be emphasized that BRCA1-mutated tumours have been reported to be highly sensitive to alkylating agents [14] . Altogether, these data indicate that the predictive value of p53 for the efficacy of anthracycline/cyclophosphamide regimen in breast cancer might differ according to the presence of BRCA1 mutations.
Breast cancers have been recently classified in genetically homogeneous subgroups that are thought to derive from different progenitors [15] . Particularly, basal-like breast cancers refer to a molecular subgroup that does not express oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2), and does express cytokeratin 5/6 or epidermal growth factor receptor [16] . This subgroup roughly corresponds to clinically described triplenegative tumours that exhibit a negative immunostaining for ER, PgR and HER2 and a higher chemosensitivity [17] . Interestingly, this latter molecular group is more likely to carry BRCA1 mutations, together with TP53 gene mutations.
We previously hypothesized that the predictive value of a single biomarker could rely on the genetic background on the tumour and that different breast cancers subgroups may have different predictive markers of response to chemotherapy [12, 18] . In the present study, we have evaluated the predictive value of p53 expression for the efficacy of a preoperative 5-fuorouracil, epirubicin and cyclophosphamide (FEC) or 5-fuorouracil, doxorubicin and cyclophosphamide (FAC) regimen according to the molecular classes defined using ER, PgR and HER2 expressions.
patients and methods

patients and treatment
Patients were retrospectively selected to have presented a breast adenocarcinoma treated with a preoperative chemotherapy that combined FEC or FAC regimen, intravenously every 3 weeks for 4-6 cycles in two French Cancer Centres (Centre Jean Perrin, Clermont Ferrand, and Institut Gustave Roussy, Villejuif). In addition, immunohistochemical determination of p53, ER, PgR and HER2 status of the primary tumour were required to include the patients in the present analysis.
histopathological analyses
Immunostaining has been carried out with automated immunostainers (ventana Benchmark). Tumour grade was defined on tumour biopsy (core needle biopsy) before chemotherapy. ER, PgR and HER2 expression were routinely determined by immunohistochemistry according to local guidelines or, when unavailable, on residual cancer tissue after mastectomy (n = 16 patients). Tumours were classified as ER or PgR positive if they exhibited at least 10% of stained cancer cells. The HercepTest scoring method was used for the determination of c-erbB-2 status (0, 1+: negative; 2+, 3+: positive [19] ). Evaluation of TP53 accumulation was done with the DO7 clone (Novocastra, UK; dilution 1 : 250 at the Institut Gustave Roussy [20] , and 1 : 200 at the Centre Jean Perrin). This antibody has been previously reported to detect most of the p53 point mutations [21] [22] [23] . Tumours were classified as p53 positive if they exhibited at least 1% of stained cells. Tumour response to chemotherapy was classified by histopathologic analysis according to Chevallier's classification. In our study, pathological complete responses (pCRs) were defined as Chevallier level 1 (complete disappearance of any tumour cell in the breast or axilla) or level 2 (persistence of isolated in situ carcinoma) [24] .
statistical analysis
For statistical analysis, differences in proportions were evaluated by the chisquare test or Fisher's exact test. We used a logistic regression model to approximate the risk ratio of achieving a pCR first in univariate analyses and then in multiple regression analysis according to baseline factors (clinical tumour size before chemotherapy (cT), tumour grade, ER, PgR, HER2 and p53 expression Table 1 . Briefly, 184 patients (63%) had a clinical T2 tumour and 100 patients (34%) had a grade III tumour. A triplenegative phenotype was found in 120 tumours (41%). It must be pointed out that this rate is higher than expected due to the fact that (i) patients were retrospectively selected to have received a preoperative chemotherapy and (ii) the p53 staining was carried out in only 173 non-triple-negative cases since the goal was to compare predictive value of p53 staining according original article Annals of Oncology to molecular classes. A p53-positive immunohistostaining was detected in 158 tumours (54%) and was associated with high tumour grade (P = 0.002, Table 1 ) and ER negativity (P = 0.04). As p53 staining was highly heterogeneous within tumoural samples, no other cut-off has been studied.
predictive parameters for pCR
From 1987 to 1995, 293 patients had their needle biopsy studied. pCR occurred in 28 of the 293 cases (9.6%). The pCR rates according to clinicopathological characteristics are reported in Table 2 . High grade [relative risk (RR) = 3.8, 95% confidence interval (CI) = 1.6-8.9, P = 0.002], ER negativity (RR = 3.4, 95% CI = 1.4-8.2, P = 0.007), PgR negativity (RR = 4.0, 95% CI = 1.3-11.9, P = 0.02) and triple negativity (RR = 5.0, 95% CI = 2.0-12.2, P = 0.0004) were good predictors of pCR achievement in the univariate analysis ( Table  2 ). p53-positive immunostaining was not associated with a significantly higher rate of pCR (RR = 1.9, 95% CI = 0.8-4.3, P = 0.12). In the multivariate analysis, high grade (RR = 2.6, 95% CI = 1.1--6.2, P = 0.04) and triple-negative phenotype (RR = 3.9, 95% CI = 1.4-10.4, P = 0.007) were statistically associated with pCR.
predictive value of p53 immunostaining according to molecular classes
We next evaluated the pCR rates according to p53 immunostainings and molecular classes (Table 3) . Interestingly, the association between p53-positive immunostaining in triplenegative tumours and pCR was almost significant (RR = 2.5, 95% CI = 0.9-7.5, P = 0.08), where the pCR proportions were 22% and 10% in p53+ and p532 triple-negative tumours, respectively. At the opposite, pCR proportions were 3% and 4% in patients with p53+ and p532 non-triple-negative tumours, respectively (RR = 0.7, 95% CI = 0.2-3.3, P = 0.69). p53+/ triple-negative tumours exhibited a 5.1-fold increase in the probability of pCR as compared with other phenotypes (95% CI = 2.2-11.3, P < 0.001). There was a trend for an interaction between p53 and triple-negative status (ratio for interaction: 3.5, P = 0.19).
discussion
In the present study, we have reported that the predictive value of p53 immunostaining for the efficacy of primary FEC regimen may differ according to molecular subclasses. p53+/triple-negative tumours exhibited a higher rate of pCR (22%) as compared with both p532/triple-negative (10%) and non-triple-negative tumours (4%). As previously stated, the predictive value of p53 for the efficacy of chemotherapy is a matter of controversies. One of the main explanation of the discrepancies reported in results among studies is the various methods used to assess the p53 status. Interestingly, studies which aimed at determining the predictive value of p53 were also very heterogeneous in terms of patient characteristics and drug regimen. As an illustration, in the study reported by Geisler et al. [25] most patients (72%) had low-or intermediate-grade tumours which are more likely to belong to luminal-A/BRCA1-nonmutated tumours; this study concluded that TP53 mutations were associated with primary resistance to neoadjuvant doxorubicin therapy. At the opposite, in the study reported by Bertheau et al. [5] , most patients had ER-negative and high-grade tumours, which are more likely to be basal like/BRCA1 mutated. Unsurprisingly, TP53 status was reported to be a predictive factor for response to the dose-dense neoadjuvant epirubicin-cyclophosphamide regimen used in this study. Although our present study is underpowered due to the small number of patients, we would speculate that p53 mutations were associated with resistance in the first study and associated with sensitivity to anthracycline-based chemotherapy in the second one. These data together with the present analysis would indicate that the heterogeneity of breast cancer molecular subclasses among studies could account for the heterogeneity of results when the predictive value of a single biomarker is investigated. It must be pointed out that studies which previously investigated the predictive value of p53 mutations/expressions were heterogeneous not only in terms of molecular classes but also regarding the use of alkylating agents. Interestingly, it has been indicated that the BRCA12/p532 phenotype is associated with a high sensitivity to alkylating agents [14] . On the basis of this background, since somatic p53 mutations are more frequent in BRCA1-mutated tumours, one might expect that p53 mutations may be associated with a higher sensitivity to regimen that includes high dose of alkylating agents. As an illustration, the team that reported that p53 mutations were associated with a higher rate of pCR used high doses of cyclophosphamide in combination with anthracyclines [26] . On the opposite, studies that reported a correlation between p53 mutations and resistance to anthracyclines-based chemotherapy did not include alkylating agents in their regimen [3, 25] . In the present study, it was not possible to assess the role of alkylating agents on the p53 predictive value. Nevertheless, patients received 500 mg/m 2 cyclophosphamide per cycle. Using this dosage, we found a trend for a higher rate of pCR in p53-positive tumours.
Overall, our study and previous reports indicate that the predictive role of p53 is a complex interplay between genetic background (BRCA1 mutations), molecular classification and the use of alkylating agents. This indicates that the predictive value of p53 status should be determined in more homogenous molecular classes using homogenous drug regimen. Nevertheless, the sample size from our study was not large enough to detect a possible interaction between molecular classes and p53 staining. This result may be also due to discrepancies previously described between p53 function, p53 accumulation and TP53 sequencing [8, [21] [22] [23] . Beyond p53 status, the DNA damage signalling may be also disrupted by p63, p73 or ATM (product of the ataxia-telangiectasia gene) dysfunction in the triple-negative subgroup [27, 28] .
Interestingly, p53 is not the only biomarker to exhibit a classspecific predictive value for chemotherapy efficacy. TOP2A gene amplification has also been described to occur almost exclusively in HER2-overexpressing tumours and to be predictive for the efficacy of anthracyclines within this molecular class [29] . In addition, microtubule-associated protein Tau (MAP-Tau), a protein which mediates paclitaxel resistance, is low in almost all ER-negative tumours, but heterogeneous in ER-positive tumours, and may present a clinical usefulness in this latter molecular group [30] . Overall, the present study indicates that a single biomarker may exhibit a differential predictive value according to molecular classes. While on the basis of a limited number of cases, this observation, which did not reached the statistical significance threshold (P = 0.08), indicates that further investigations on predictive value of drug-specific biomarkers should be carried 
